Kilitch Drugs (India) LtdQ1 FY23Pharmaceuticals & Biotechnology

Kilitch Drugs (India) Ltd

Q1 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Revenue guidance

Category 2

→Company expects robust growth in Ethiopia business in FY 2023-24 as government has agreed in principle to provide foreign exchange to support imports, enabling full utilization of Cephalosporin plant capacity.
→Overall sales growth of 30% to 35% year-on-year was reported, with export commissions rising in line with sales.
→Indian pharmaceutical market projected to see double-digit growth, driven by potential increases in government healthcare spending.
→Injectable business expected to grow with plans for increased capacity at Khopoli plant; running multiple shifts planned to meet growing demand.
→Exports from the Ethiopian plant to other African countries (Sudan, Uganda, Kenya, Tanzania, Nigeria) anticipated within 1-2 years after product registration and approvals.
→Capacity expansions and government contracts are expected to drive increased production volumes and revenues.
→Continued focus on contract manufacturing and exploring opportunities to monetize non-core land assets for capital deployment.

Category 2

→Kilitch Drugs India Limited expects continued robust growth in earnings and profits driven by multiple factors.
→Domestic pharma market anticipated to grow at double-digit rates, supported by increased government healthcare spend.
→Ethiopian manufacturing unit poised for a robust ramp-up, with government backing and forex allocation improving operational capacity.
→EBITDA margins have shown improvement (from 14.8% to 18.8%) and management aims for further margin enhancements in coming quarters.
→New Khopoli plant expansion (> INR 100 crores capex) will augment capacity, supporting growth, especially in contract manufacturing.
→EPS grew significantly to INR 10.09 in FY23 from INR 6.76, with management optimistic on sustaining this growth trajectory.
→Overall, growth will be fueled by expansion in both domestic and export markets, capacity ramp-ups, and operational efficiencies.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Kilitch Drugs (India) Ltd and 1,400+ other companies.

Yes

→The company plans to fund the Khopoli plant expansion primarily through external loans, with bank sanctions already obtained for the funding.
→There is no mention of any planned equity fundraising related to this expansion or otherwise.
→For non-core assets like land in Bhiwandi, monetization might be considered at the right time, but the current focus remains on pharma operations and the capex projects.
→The company aims to sustain growth through internal accruals and bank funding rather than new equity issuance.

→No specific numeric details on the current or expected order book were mentioned in the transcript.
→The management expressed confidence in demand growth, citing an 8% to 12% year-on-year growth trend in the pharma market.
→The additional capacity at the Khopoli plant was conceptualized anticipating increased demand and possible capacity shortfalls.
→While no formal offtake agreements for the new capacity were signed, the company expects existing customers to create demand based on market trends.
→In Ethiopia, government tenders have been delayed due to forex issues but are expected to be addressed soon, potentially boosting orders.
→The private market currently accounts for Ethiopian sales, with supply to government expected to start after forex support.
→Overall, management is optimistic about a robust sales ramp-up with capacity expansions supporting growth.

Yes

→Khopoli Plant Expansion:
→ - Estimated capital expenditure: More than INR 100 crores.
→ - Funding: Mostly through external bank loans; sanctions have been received.
→ - Timeline: Plant construction to take about two years; production expected to start from March 2025 onwards.
→ - Capacity details to be consolidated and shared later.
→Ethiopia Plant:
→ - Current operations ramping up after initial struggles.
→ - Plans to increase supply and possibly export within African countries.
→ - Government support with tax benefits: Four years of income tax exemption starting July 2021 till July 2025.
→Non-core assets:
→ - Land in Bhiwandi may be monetized at the right opportunity but focus remains on pharma-related capex.
→Overall, strategic investments focus on expanding manufacturing capacity to meet growing demand in both domestic and export markets.

How does Kilitch Drugs (India) Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Kilitch Drugs (India) Ltd

Rev 2Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Kilitch Drugs (India) Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.